Anti-cancer compositions
US5891864A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Nov 3, 1995 |
| Grant date | Apr 6, 1999 |
| Priority date | — |
| Expiry date | Nov 3, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an anti-cancer composition containing acridine derivatives and guanosine compounds. In the composition of the present invention, the acridine derivative and the guanosine compound are present in the weight ratio of 1:0.1-5.0, preferably 1:0.3-3.0 and more preferably 1:0.5-1.5. In the composition of the present invention, most preferably the acridine derivative is acriflavine neutral and the guanosine compound is guanosine hydrate. Although acridine derivatives and guanosine compounds used as an active ingredient in the present composition have substantially no anti-cancer effect when they are used individually, the combination of acriflavine neutral and guanosine hydrate which potentiates the effect of acriflavine neutral, i.e. the composition(AG60) according to the present invention, exhibits reduced toxicity and increased anti-cancer effect in comparison to the use of acriflavine neutral or guanosine hydrate alone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.